Wockhardt Bio incorporates new wholly owned subsidiary in Ireland

Objects of Wockhardt Antibiotics (Ireland) Limited are in line with the main objects of the Company and the new entity will help to channelize the Company’s antibiotic products across European Union.

Medical Dialogues team had earlier reported that a 15-year-old US patient with Acute Myeloid Leukemia (AML), a type of blood and bone marrow cancer, had been successfully cured of a severe, drug-resistant infection following treatment with Zaynich (Zidebactam/Cefepime, WCK 5222) under compassionate use.

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt’s New Drug Discovery programme has focussed on Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is a company where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable “Superbugs”. It has a comprehensive Drug Discovery team and clinical organisation. Wockhardt is employing around ~2600 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 79% of its global revenues coming from international businesses.